Unexpected Activity of Two Enzymes Helps Explain Why Liver Cancer Drugs Fail
Researchers at University of California San Diego School of Medicine have discovered that lack of two types of enzymes can lead to liver disease and cancer in mice. In human liver tumors, they found that deficiencies in these two enzymes, Shp2 and Pten, are associated with poor prognosis. The study, published December 13 by Cell Reports, provides a new understanding of liver cancer development, new therapeutic approach and new mouse model for studying the disease.